This website uses cookies. For more information please contact us or consult our privacy policy.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

David Wildman
David R. Wildman
Associate
New York +1 212 841 1202 dwildman@cov.com Download V-card

David Wildman joined the firm in 2015. He represents and counsels clients engaged in complex transactions involving technology, intellectual property and data. In this role, Mr. Wildman regularly provides advice relating to data protection and commercialization, the development and exploitation of “big data” analytical tools and predictive models, and cloud services agreements. Mr. Wildman represents clients in a wide array of industries, including health technology (or “eHealth”), travel, defense, sports, media, and finance.

  • Teva Pharmaceutical Industries in an eHealth collaboration with IBM, including a cloud services agreement for the deployment of IBM’s Watson Health Cloud as Teva’s global patient technology platform.
  • American Airlines in technology and data distribution agreements with travel industry participants.
  • A health technology company in development and collaboration agreements with various EHR providers.
  • A pharmaceutical company in a data licensing agreement with a health analytics and “big data” company.
  • A biotech company in an intellectual property licensing agreement with a product manufacturer.   
  • A pharmaceutical company with its Terms of Service for a mobile health app.
  • An aerospace company in a licensing dispute with a software vendor.
  • Conducted technology and IP due diligence in connection with a number of M&A projects.
  • Performing IP due diligence and preparing technology transfer and licensing agreements for a client in the travel industry.
  • Assisting the preparation of a service level agreement for a client in the sports industry.

Pro Bono

  • Obtained cancellation of removal for a 30-year legal permanent resident in removal proceedings. 

Previous Experience

  • Performed IP due diligence on behalf of an investor participating in a Series C funding round of a medical device company.
  • Facilitated the development of a global licensing program, involving thousands of IP assets, for a leading media company.
  • Represented a Fortune 500 company in an inter partes review at the USPTO.